Item Type | Name |
Academic Article
|
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
|
Academic Article
|
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
|
Academic Article
|
Influenza among hospitalized adults with leukemia.
|
Academic Article
|
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.
|
Academic Article
|
Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia.
|
Academic Article
|
Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
|
Academic Article
|
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.
|
Academic Article
|
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
|
Academic Article
|
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
|
Academic Article
|
Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival.
|
Academic Article
|
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.
|
Academic Article
|
Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia.
|
Academic Article
|
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia.
|
Academic Article
|
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses.
|
Academic Article
|
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
|
Academic Article
|
HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.
|
Academic Article
|
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression.
|
Academic Article
|
High incidence of IDH mutations in acute myeloid leukaemia with cuplike nuclei.
|
Academic Article
|
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
|
Academic Article
|
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
|
Academic Article
|
Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia.
|
Academic Article
|
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
|
Academic Article
|
High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement.
|
Academic Article
|
Acute lymphoblastic leukemia following preleukemic syndromes in adults.
|
Academic Article
|
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
|
Academic Article
|
Selection of chronic lymphocytic leukemia binding peptides.
|
Academic Article
|
An in vivo propagated human acute myeloid leukemia expressing ABCA3.
|
Academic Article
|
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
|
Academic Article
|
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia.
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Leukemia, T-Cell
|
Concept
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Leukemia, Erythroblastic, Acute
|
Concept
|
Leukemia, B-Cell
|
Concept
|
Leukemia, Myelomonocytic, Chronic
|
Concept
|
Leukemia, Myeloid, Accelerated Phase
|
Concept
|
Leukemia, Monocytic, Acute
|
Concept
|
Myeloid-Lymphoid Leukemia Protein
|
Concept
|
Leukemia, Promyelocytic, Acute
|
Concept
|
Leukemia, Experimental
|
Concept
|
Leukemia, Lymphoid
|
Concept
|
Leukemia, Myelomonocytic, Acute
|
Concept
|
Leukemia, Myeloid
|
Concept
|
Leukemia
|
Concept
|
Leukemia, Myeloid, Acute
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
Concept
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Leukemia, Biphenotypic, Acute
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
Concept
|
Leukemia, Prolymphocytic
|
Concept
|
Leukemia, Myeloid, Chronic-Phase
|
Concept
|
Graft vs Leukemia Effect
|
Academic Article
|
Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment.
|
Academic Article
|
Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.
|
Academic Article
|
Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.
|
Academic Article
|
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
|
Academic Article
|
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
|
Academic Article
|
Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.
|
Academic Article
|
Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.
|
Academic Article
|
Flow cytometric analysis of cytokinetics of L3-acute lymphoblastic leukemia/lymphoma.
|
Academic Article
|
High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia.
|
Academic Article
|
Acute lymphoblastic leukemia in adults.
|
Academic Article
|
Prognostic value of DNA/RNA flow cytometry in myeloblastic and lymphoblastic leukemia in adults: RNA content and S-phase predict remission duration and survival in multi-variate analysis.
|
Academic Article
|
Use of prognostic factors in deciding therapy for adult acute lymphoblastic leukemia: new approaches at Memorial Sloan-Kettering Cancer Center (MSKCC).
|
Academic Article
|
Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
|
Academic Article
|
Detection of luxol-fast-blue positive cells in human promyelocytic leukemia cell line HL-60.
|
Academic Article
|
Induction of in vitro proliferation and maturation of human aneuploid myelogenous leukemic cells.
|
Academic Article
|
Recognition of central nervous system leukemia by flow cytometry.
|
Academic Article
|
Effect of very high-dose thymidine infusions on leukemia and lymphoma patients.
|
Academic Article
|
Changes of cellular markers during differentiation of HL-60 promyelocytes to macrophages as induced by T lymphocyte conditioned medium.
|
Academic Article
|
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.
|
Academic Article
|
Flow cytometry. Clinical and research applications in hematologic malignancies.
|
Academic Article
|
Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
|
Academic Article
|
Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow.
|
Academic Article
|
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
|
Academic Article
|
Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing.
|
Academic Article
|
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
|
Academic Article
|
Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia.
|
Academic Article
|
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.
|
Academic Article
|
PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells.
|
Academic Article
|
Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes.
|
Academic Article
|
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
|
Academic Article
|
Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.
|
Academic Article
|
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
|
Academic Article
|
Cytokine expression of T cells in chronic myeloid leukemia.
|
Academic Article
|
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells.
|
Academic Article
|
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
|
Academic Article
|
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
|
Academic Article
|
Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL.
|
Academic Article
|
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.
|
Academic Article
|
PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation.
|
Academic Article
|
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
|
Academic Article
|
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.
|
Academic Article
|
A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia.
|
Academic Article
|
Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells.
|
Academic Article
|
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells.
|
Academic Article
|
Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML.
|
Academic Article
|
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
|
Academic Article
|
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
|
Academic Article
|
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
|
Academic Article
|
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.
|
Academic Article
|
Targeting the leukemia microenvironment.
|
Academic Article
|
Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.
|
Academic Article
|
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.
|
Academic Article
|
Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin.
|
Academic Article
|
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
|
Academic Article
|
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
|
Academic Article
|
MicroRNA 29b functions in acute myeloid leukemia.
|
Academic Article
|
Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.
|
Academic Article
|
Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells.
|
Academic Article
|
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
|
Academic Article
|
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
|
Academic Article
|
Low expression of PP2A regulatory subunit B55a is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
|
Academic Article
|
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
|
Academic Article
|
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
|
Academic Article
|
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
|
Academic Article
|
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
|
Academic Article
|
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
|
Academic Article
|
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.
|
Academic Article
|
The protein phosphatase 2A regulatory subunit B55a is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
|
Academic Article
|
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
|
Academic Article
|
T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma.
|
Academic Article
|
Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
|
Academic Article
|
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.
|
Academic Article
|
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization.
|
Academic Article
|
Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro.
|
Academic Article
|
Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside.
|
Academic Article
|
Idarubicin in acute leukemia: results of US trials.
|
Academic Article
|
Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia.
|
Academic Article
|
Prognostic factors in acute lymphoblastic leukemia in adults: the Memorial Hospital experience.
|
Academic Article
|
Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells.
|
Academic Article
|
Childhood CML in blastic stage: an analysis of cell markers and cell kinetics.
|
Academic Article
|
Heterogeneity of cell lineages in L3 leukemias.
|
Academic Article
|
Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma.
|
Academic Article
|
Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
|
Academic Article
|
Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA.
|
Academic Article
|
Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
|
Academic Article
|
Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
|
Academic Article
|
Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance.
|
Academic Article
|
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
|
Academic Article
|
Epidemiology of influenza A virus infection in patients with acute or chronic leukemia.
|
Academic Article
|
Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia.
|
Academic Article
|
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
|
Academic Article
|
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.
|
Academic Article
|
Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes.
|
Academic Article
|
A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia.
|
Academic Article
|
Semi-automated PCR method for quantitating MDR1 expression.
|
Academic Article
|
Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Academic Article
|
2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome.
|
Academic Article
|
Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission.
|
Academic Article
|
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
|
Academic Article
|
Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
|
Academic Article
|
Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines.
|
Academic Article
|
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
|
Academic Article
|
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.
|
Academic Article
|
Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule.
|
Academic Article
|
Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
|
Academic Article
|
Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes.
|
Academic Article
|
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
|
Academic Article
|
Human A1 expression in acute myeloid leukemia and its relationship to Bcl-2 expression.
|
Academic Article
|
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
|
Academic Article
|
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
|
Academic Article
|
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
|
Academic Article
|
Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy.
|
Academic Article
|
A method for functional evaluation of caspase activation pathways in intact lymphoid cells using electroporation-mediated protein delivery and flow cytometric analysis.
|
Academic Article
|
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
|
Academic Article
|
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.
|
Academic Article
|
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival.
|
Academic Article
|
The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.
|
Academic Article
|
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
|
Academic Article
|
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
|
Academic Article
|
Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.
|
Academic Article
|
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
|
Academic Article
|
The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.
|
Academic Article
|
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
|
Academic Article
|
Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects.
|
Academic Article
|
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
|
Academic Article
|
Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
|
Academic Article
|
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.
|
Academic Article
|
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
|
Academic Article
|
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
|
Academic Article
|
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
|
Academic Article
|
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.
|
Academic Article
|
Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
|
Academic Article
|
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
|
Academic Article
|
ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
|
Academic Article
|
Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells.
|
Academic Article
|
PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.
|
Academic Article
|
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
|
Academic Article
|
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
|
Academic Article
|
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
|
Academic Article
|
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
|
Academic Article
|
HOX expression patterns identify a common signature for favorable AML.
|
Academic Article
|
Functional proteomic profiling of AML predicts response and survival.
|
Academic Article
|
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
|
Academic Article
|
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
|
Academic Article
|
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
|
Academic Article
|
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.
|
Academic Article
|
Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.
|
Academic Article
|
Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling.
|
Academic Article
|
Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia.
|
Academic Article
|
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
|
Academic Article
|
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
|
Academic Article
|
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
|
Academic Article
|
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
|
Academic Article
|
Effects of PPAR? Ligands on Leukemia.
|
Academic Article
|
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.
|
Academic Article
|
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
|
Academic Article
|
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
|
Academic Article
|
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
|
Academic Article
|
XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
|
Academic Article
|
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
|
Academic Article
|
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
|
Academic Article
|
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.
|
Academic Article
|
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
|
Academic Article
|
The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis.
|
Academic Article
|
Retinoids and cancer therapy.
|
Academic Article
|
Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia.
|
Academic Article
|
Proliferation of hematopoietic cells is accompanied by suppressed expression of heat shock protein 70.
|
Academic Article
|
The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells during the cell cycle.
|
Academic Article
|
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
|
Academic Article
|
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
|
Academic Article
|
A study of multidrug resistance and cell kinetics in a child with near-haploid acute lymphoblastic leukemia.
|
Academic Article
|
Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA.
|
Academic Article
|
Implications of 'cell kill' for the treatment of acute myelogenous leukemia: can the cure rate be increased?
|
Academic Article
|
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
|
Academic Article
|
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
|
Academic Article
|
A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.
|
Academic Article
|
Cellular ras oncogene expression and cell cycle measured by flow cytometry in hematopoietic cell lines.
|
Academic Article
|
Cell kinetics of leukemia.
|
Academic Article
|
[Oncogens and cancer. Review and a new method for measuring the gene expression in relation to the cell cycle].
|
Academic Article
|
Multiparameter flow cytometry. Part II. application in hematology.
|
Academic Article
|
Bone marrow biopsy instead of 'marrow juice' for cell kinetic analysis. Comparison of bone marrow biopsy and aspiration material.
|
Academic Article
|
Flow cytometry in clinical cancer research.
|
Academic Article
|
Cell survival kinetics in peripheral blood and bone marrow during total body irradiation for marrow transplantation.
|
Academic Article
|
Lymphoblastic neoplasia in a homosexual patient with Kaposi's sarcoma.
|
Academic Article
|
[Pro and con: Aggressive or conventional treatment of chronic myelogenous leukemia. Arguments in favor of aggressive treatment].
|
Academic Article
|
[Summary: Therapy of chronic myelogenous leukemia--prognosis].
|
Academic Article
|
Acute myeloblastic leukemia following non-Hodgkin lymphoma in an adolescent. A report of a case with preleukemic syndrome, and review of the literature.
|
Academic Article
|
Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia.
|
Academic Article
|
Cell kinetics in acute leukemia: a critical reevaluation based on new data.
|
Academic Article
|
Quantitation of chemotherapy-induced cytoreduction in acute leukemia.
|
Academic Article
|
A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia.
|
Academic Article
|
Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha.
|
Academic Article
|
Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis.
|
Academic Article
|
Interleukin-3 priming in acute myeloid leukaemia patients.
|
Academic Article
|
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
|
Academic Article
|
Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study.
|
Academic Article
|
Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells.
|
Academic Article
|
Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin.
|
Academic Article
|
Low incidence of MDR1 expression in acute promyelocytic leukaemia.
|
Academic Article
|
Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients).
|
Academic Article
|
Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology.
|
Academic Article
|
Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy.
|
Academic Article
|
Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid.
|
Academic Article
|
Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia.
|
Academic Article
|
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.
|
Academic Article
|
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Academic Article
|
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
|
Academic Article
|
Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.
|
Academic Article
|
Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes.
|
Academic Article
|
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
|
Academic Article
|
Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia.
|
Academic Article
|
Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents.
|
Academic Article
|
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
|
Academic Article
|
Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells.
|
Academic Article
|
Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities.
|
Academic Article
|
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
|
Academic Article
|
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
|
Academic Article
|
Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.
|
Academic Article
|
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
|
Academic Article
|
Functional expression of TRAIL by lymphoid and myeloid tumour cells.
|
Academic Article
|
Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification.
|
Academic Article
|
Cytokine-regulated expression of survivin in myeloid leukemia.
|
Academic Article
|
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
|
Academic Article
|
Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.
|
Academic Article
|
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.
|
Academic Article
|
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.
|
Academic Article
|
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
|
Academic Article
|
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
|
Academic Article
|
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
|
Academic Article
|
Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis.
|
Academic Article
|
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
|
Academic Article
|
Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization.
|
Academic Article
|
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
|
Academic Article
|
Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.
|
Academic Article
|
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
|
Academic Article
|
Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
|
Academic Article
|
Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure.
|
Academic Article
|
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
|
Academic Article
|
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
|
Academic Article
|
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
|
Academic Article
|
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.
|
Academic Article
|
Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells".
|
Academic Article
|
Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin.
|
Academic Article
|
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
|
Academic Article
|
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications.
|
Academic Article
|
TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells.
|
Academic Article
|
Potential role of sorafenib in the treatment of acute myeloid leukemia.
|
Academic Article
|
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
|
Academic Article
|
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
|
Academic Article
|
Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.
|
Academic Article
|
Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.
|
Academic Article
|
Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.
|
Academic Article
|
1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
|
Academic Article
|
The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.
|
Academic Article
|
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1a-mediated down-regulation of CXCL12.
|
Academic Article
|
MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.
|
Academic Article
|
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
|
Academic Article
|
Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
|
Academic Article
|
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
|
Academic Article
|
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
|
Academic Article
|
CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
|
Academic Article
|
Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia.
|
Academic Article
|
PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
|
Academic Article
|
BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.
|
Academic Article
|
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
|
Academic Article
|
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-?B mediates chemoresistance.
|
Academic Article
|
Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.
|
Academic Article
|
Different sensitivity of chromatin to acid denaturation in quiescent and cycling cells as revealed by flow cytometry.
|
Academic Article
|
Surface marker analysis and flow cytometric studies of acute nonlymphocytic leukemias in children and young adults.
|
Academic Article
|
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.
|
Academic Article
|
Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow.
|
Academic Article
|
Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia.
|
Academic Article
|
DNA and RNA analysis by flow cytometry of the leukemia in AKR mice.
|
Academic Article
|
Common acute lymphoblastic leukemia characterized by four different DNA stemlines with heterogeneity in RNA content, antigen expression and sensitivity to chemotherapy.
|
Academic Article
|
DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: correlation of FAB classification with DNA stemline and proliferation.
|
Academic Article
|
Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia.
|
Academic Article
|
Acute non-lymphoblastic leukemia after treatment of nodular lymphoma with human leukocyte interferon.
|
Academic Article
|
[Comparison of the therapeutic efficacity of 2 induction protocols in acute myeloid leukemia using exact quantification of bone marrow cellularity].
|
Academic Article
|
Non-T, non-B acute lymphoblastic leukemia (L3) with t(8;22) and two 14q+ chromosomes.
|
Academic Article
|
Characterization of hematologic malignancies by flow cytometry.
|
Academic Article
|
A knowledge-based system for the interpretation of flow cytometry data in leukemias and lymphomas.
|
Academic Article
|
Acanthamoeba meningoencephalitis after bone marrow transplantation.
|
Academic Article
|
Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
|
Academic Article
|
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.
|
Academic Article
|
Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis.
|
Academic Article
|
CD30 ligand is expressed on resting normal and malignant human B lymphocytes.
|
Academic Article
|
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
|
Academic Article
|
Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.
|
Academic Article
|
Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.
|
Academic Article
|
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents.
|
Academic Article
|
Apoptosis. Molecules and mechanisms.
|
Academic Article
|
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
|
Academic Article
|
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
|
Academic Article
|
Mechanisms of drug resistance in AML.
|
Academic Article
|
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
|
Academic Article
|
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
|
Academic Article
|
Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complex.
|
Academic Article
|
Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells.
|
Academic Article
|
Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
|
Academic Article
|
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
|
Academic Article
|
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
|
Academic Article
|
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.
|
Academic Article
|
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
|
Academic Article
|
The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation.
|
Academic Article
|
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
|
Academic Article
|
Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.
|
Academic Article
|
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
|
Academic Article
|
Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
|
Academic Article
|
Apoptosis in leukemias: regulation and therapeutic targeting.
|
Academic Article
|
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.
|
Academic Article
|
The organic arsenic derivative GMZ27 induces PML-RARa-independent apoptosis in myeloid leukemia cells.
|
Academic Article
|
Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
|
Academic Article
|
CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
|
Academic Article
|
Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
|
Academic Article
|
Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts.
|
Academic Article
|
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).
|
Academic Article
|
Hematopoietic colony-stimulating factors.
|
Academic Article
|
The PML gene encodes a phosphoprotein associated with the nuclear matrix.
|
Academic Article
|
Minimal residual disease in hematologic malignancies.
|
Academic Article
|
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
|
Academic Article
|
Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization.
|
Academic Article
|
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
|
Academic Article
|
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
|
Academic Article
|
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
|
Academic Article
|
CD38 in hematopoietic malignancies.
|
Academic Article
|
Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor.
|
Academic Article
|
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
|
Academic Article
|
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
|
Academic Article
|
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
|
Academic Article
|
PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
|
Academic Article
|
Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation.
|
Academic Article
|
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
|
Academic Article
|
Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
|
Academic Article
|
CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure.
|
Academic Article
|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
|
Academic Article
|
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
|
Academic Article
|
Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor.
|
Academic Article
|
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.
|
Academic Article
|
GM-CSF in combination with cytotoxic chemotherapy in AML patients.
|
Academic Article
|
Surface immunoglobulin light chain expression in pre-B cell leukemias.
|
Academic Article
|
Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature.
|
Academic Article
|
Biosynthesis of ferritin subunits from different cell lines of HL-60 human promyelocytic leukaemia cells and the release of acidic isoferritin-inhibitory activity against normal granulocyte-macrophage progenitor cells.
|
Academic Article
|
Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells.
|
Academic Article
|
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
|
Academic Article
|
The effect of calcium channel blockers on the outcome of acute myeloid leukemia.
|
Academic Article
|
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
|
Academic Article
|
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
|
Academic Article
|
Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment.
|
Academic Article
|
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
|
Academic Article
|
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
|
Academic Article
|
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.
|
Academic Article
|
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
|
Academic Article
|
Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
|
Academic Article
|
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
|
Academic Article
|
Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.
|
Academic Article
|
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
|
Academic Article
|
MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.
|
Academic Article
|
Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy.
|
Academic Article
|
Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis.
|
Academic Article
|
Phosphorylation of GSK3a/? correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients.
|
Academic Article
|
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
|
Academic Article
|
Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes.
|
Academic Article
|
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
|
Academic Article
|
TGF-?-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
|
Academic Article
|
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
|
Academic Article
|
The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.
|
Academic Article
|
Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport.
|
Academic Article
|
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade
|
Academic Article
|
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
|
Academic Article
|
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
|
Academic Article
|
Higher levels of expression of BCL-2 and BCL-XL in poor prognosis monosomy 5 and monosomy 7} acute myeloid leukemia (AML) cells than in good prognosis (inversion 16 and translocation 8;21) aml cells
|
Academic Article
|
The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 Mutations
|
Academic Article
|
Targeting survivin in leukemia
|
Academic Article
|
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia
|
Academic Article
|
Kinetic and biochemical modulation of pyrimidine antimetabolites in therapy of acute leukemia
|
Academic Article
|
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
|
Academic Article
|
Dual tel-abl fusion in a PH-negative chronic myeloid leukemia patient
|
Academic Article
|
Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia
|
Academic Article
|
Chemotherapy of acute non-lymphocytic leukemia - new cell kinetic determinants
|
Academic Article
|
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation
|
Academic Article
|
Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells
|
Academic Article
|
Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia
|
Academic Article
|
MDM2 inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation
|
Academic Article
|
Quantitation of therapy induced cytoreduction in acute myeloblastic leukemia (AML)
|
Academic Article
|
Mesenchymal stem cells (MSC) as carriers of hologically active molecules in cancer and leukemia therapy
|
Academic Article
|
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients
|
Academic Article
|
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
|
Academic Article
|
Inihibition of PI3K by LY294002 promotes apoptosis and dephosphorylates bad in myeloid leukemias
|
Academic Article
|
Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes
|
Academic Article
|
Comparison of the therapeutic efficacy of two induction regimens for acute myelocytic leukemia (AML) by accurate quantitation of bone marrow cellularity
|
Academic Article
|
High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Academic Article
|
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy
|
Academic Article
|
New directions in the biology and therapy of chronic myeloid leukemia
|
Academic Article
|
Non B- non T acute lymphoblastic leukemia (ALL)
|
Academic Article
|
Photothermolysis by laser-induced microbubbles generated around gold nanorod clusters selectively formed in leukemia cells
|
Academic Article
|
Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia
|
Academic Article
|
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network
|
Academic Article
|
Treatment of Newly-Diagnosed AML with idarubicin + ARA-C
|
Academic Article
|
Targeted therapy of acute myeloid leukemia
|
Academic Article
|
Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells
|
Academic Article
|
Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in preclinical leukemia models
|
Academic Article
|
Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport
|
Academic Article
|
Current status of treatment of acute leukemia in adults
|
Academic Article
|
Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients
|
Academic Article
|
Treatment of philadelphia chromosome positive (ph +) chronic myelogenous leukemia in blast crisis and ph + acute leukemia with high dose cytosine arabinoside (HDARAC)
|
Academic Article
|
Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs
|
Academic Article
|
Photothermal therapy of acute leukemia cells in the near-infrared region using gold nanorods CD-33 conjugates
|
Academic Article
|
Pharmacological activation of wild-type p53 in the therapy of leukemia
|
Academic Article
|
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
|
Academic Article
|
Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia
|
Academic Article
|
Treatment of Newly-Diagnosed AML with Idarubicin + ARA-C
|
Academic Article
|
Iap family of proteins as therapeutic targets for acute myeloid leukemia
|
Academic Article
|
AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth.
|
Academic Article
|
Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles.
|
Academic Article
|
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
|
Academic Article
|
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
|
Academic Article
|
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
|
Academic Article
|
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1? signaling network.
|
Academic Article
|
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
|
Academic Article
|
High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing?Variant, HDM4-S, in Bone Marrow in?Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
|
Academic Article
|
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
|
Academic Article
|
Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang.
|
Academic Article
|
Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).
|
Academic Article
|
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
|
Academic Article
|
Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.
|
Academic Article
|
Pharmacological activation of wild-type p53 in the therapy of leukemia.
|
Academic Article
|
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
|
Academic Article
|
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.
|
Academic Article
|
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
|
Academic Article
|
FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia.
|
Academic Article
|
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.
|
Academic Article
|
Focal Adhesion Kinase as a Potential Target in AML and MDS.
|
Academic Article
|
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.
|
Academic Article
|
Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
|
Academic Article
|
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells.
|
Academic Article
|
Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.
|
Academic Article
|
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
|
Academic Article
|
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
|
Academic Article
|
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
|
Academic Article
|
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
|
Academic Article
|
The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.
|
Academic Article
|
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
|
Academic Article
|
High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.
|
Academic Article
|
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
|
Academic Article
|
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
|
Academic Article
|
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
|
Academic Article
|
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
|
Academic Article
|
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells.
|
Academic Article
|
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.
|
Academic Article
|
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.
|
Academic Article
|
Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia.
|
Academic Article
|
Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.
|
Academic Article
|
Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival.
|
Academic Article
|
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.
|
Academic Article
|
Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.
|
Academic Article
|
MYC protein expression is an important prognostic factor in acute myeloid leukemia.
|
Academic Article
|
Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.
|
Academic Article
|
Role of MSC-derived galectin 3 in the AML microenvironment.
|
Academic Article
|
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
|
Academic Article
|
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
|
Academic Article
|
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
|
Academic Article
|
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.
|
Academic Article
|
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
|
Academic Article
|
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
|
Academic Article
|
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
|
Academic Article
|
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
|
Academic Article
|
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.
|
Academic Article
|
NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.
|
Academic Article
|
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
|
Academic Article
|
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
|
Academic Article
|
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine.
|
Academic Article
|
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
|
Grant
|
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
|
Grant
|
THE THERAPY OF AML
|
Grant
|
Anti-Leukemic Activity of the Novel Triterpeniod CDDO
|
Grant
|
CYTOKINE/CHEMOTHERAPY COMBINATIONS IN MYELOID LEUKEMIA
|
Grant
|
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
|
Grant
|
CELL BIOLOGY AND PHARMACOKINETICS OF LOW-DOSE ARA-C
|
Grant
|
FUNCTION OF QUIESCENT CELLS IN PEDIATRIC LEUKEMIA
|
Academic Article
|
An ARC-Regulated IL1?/Cox-2/PGE2/?-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML.
|
Academic Article
|
BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.
|
Academic Article
|
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
|
Academic Article
|
Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis.
|
Academic Article
|
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
|
Concept
|
Promyelocytic Leukemia Protein
|
Concept
|
Myeloid Cell Leukemia Sequence 1 Protein
|
Academic Article
|
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.
|
Academic Article
|
LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.
|
Academic Article
|
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
|
Academic Article
|
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
|
Academic Article
|
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.
|
Academic Article
|
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
|
Academic Article
|
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
|
Academic Article
|
Clinical value of event-free survival in acute myeloid leukemia.
|
Academic Article
|
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
|
Academic Article
|
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
|
Academic Article
|
LGALS1 acts as a pro-survival molecule in AML.
|
Academic Article
|
MDM2 inhibition: an important step forward in cancer therapy.
|
Academic Article
|
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
|
Academic Article
|
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years.
|
Academic Article
|
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
|
Academic Article
|
First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations.
|
Academic Article
|
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
|
Academic Article
|
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.
|
Academic Article
|
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.
|
Academic Article
|
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
|
Academic Article
|
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
|
Academic Article
|
Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-?-p38-ALDH2 pathway.
|
Academic Article
|
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
|
Academic Article
|
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
|
Academic Article
|
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
|
Academic Article
|
Loss of expression of both miR-15/16 loci in CML transition to blast crisis.
|
Academic Article
|
High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
|
Academic Article
|
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.
|
Academic Article
|
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.
|
Academic Article
|
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
|
Academic Article
|
DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
|
Academic Article
|
Therapeutic implications of menin inhibition in acute leukemias.
|
Academic Article
|
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
|
Academic Article
|
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
|
Academic Article
|
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
|
Academic Article
|
Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
|
Academic Article
|
Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
|
Academic Article
|
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition.
|
Academic Article
|
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy.
|
Academic Article
|
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
|
Academic Article
|
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.
|
Academic Article
|
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
|
Academic Article
|
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia.
|
Academic Article
|
Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.
|
Academic Article
|
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
|
Academic Article
|
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
|
Academic Article
|
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
|
Academic Article
|
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
|
Academic Article
|
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
|
Academic Article
|
Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway.
|
Academic Article
|
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
|
Academic Article
|
Correction to: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.
|
Academic Article
|
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.
|
Academic Article
|
Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
|
Academic Article
|
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
|
Academic Article
|
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment.
|
Academic Article
|
A phase two study of high dose blinatumomab in Richter's syndrome.
|
Academic Article
|
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
|
Academic Article
|
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
|
Academic Article
|
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
|
Academic Article
|
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
|
Academic Article
|
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model.
|
Academic Article
|
Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia.
|
Academic Article
|
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases.
|
Academic Article
|
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
|
Academic Article
|
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
|
Academic Article
|
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
|
Academic Article
|
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
|
Academic Article
|
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
|
Academic Article
|
Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia.
|
Academic Article
|
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
|
Academic Article
|
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
|
Academic Article
|
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
|
Academic Article
|
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
|
Academic Article
|
Cigarette smoke exposure accelerates AML progression in FLT3-ITD models.
|
Academic Article
|
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia.
|
Academic Article
|
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
|
Academic Article
|
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
|
Academic Article
|
Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
|
Academic Article
|
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
|